I'll share my live trade ideas in real time with our members of the Benzinga Option School or Trading Waves, so make sure to join and see how I'm trading it. I hope to see you there soon.

Goldman Sachs analyst warns 340B reforms could shift profits to biopharma, benefiting companies like Merck and Gilead. Proposed Medicaid cuts may create risks for biopharma, impacting drugs like ...

29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq ... today announced that the company will present three posters for its lead therapeutic candidate, efzofitimod, at the American Thoracic ...

29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines ...

While the benefits may not be immediately apparent, this approach has a good record of delivering long-term gains. Pharmaceutical companies such as Denmark's Lundbeck (DK:HLUN.B) face difficulties ...

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

While large pharma spending on R&D actually increased by 9.7% in 2024, according to the report, R&D spending from 13 companies including Roche, Johnson & Johnson and Novartis is expected to ...